The purpose of this study is to assess the safety of telbermin applied topically to chronic, diabetic foot ulcers and to explore the possible effectiveness of this treatment to induce healing of diabetic foot ulcers.

Ages Eligible for Study:  18 Years   -   80 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Type 1 or 2 diabetes mellitus.
• Single, full-thickness (i.e. extending into the subcutaneous tissue or beyond) ulcer of the foot that does not involve bone, tendons, ligaments, or muscle below the malleolus.
• Chronic ulcer with a duration of >4 weeks but <6 months.

Exclusion Criteria:

• History of neoplasia or current neoplasia (with the exception of non-melanoma skin cancer).
• Proliferative diabetic retinopathy or wet age-related macular degeneration.
• Active ulcer infection or cellulitis of any ulcer.
• Immunosuppressive treatment, including radiation therapy, corticosteroids, and chemotherapy.
• Pregnancy or lactation.
• Multiple ulcers in the study foot.
• Known prior inability to complete required study visits during treatment period.
• Current use of any other investigational drug.
• Previous use of a platelet-derived or other growth factors on the study ulcer within the past 3 months.